Effects of ODM-109 on Respiratory Function in Patients With Amyotrophic Lateral Sclerosis

Amyotrophic Lateral Sclerosis Clinical Trial

— ALS  

Official title:

Effects of ODM-109 on Respiratory Function in Patients With ALS. A Randomized, Double Blind, Placebo-controlled, Cross-over, 3-period, Multicenter Study With Open-label Follow-up Extension

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02487407
• Other study ID #: 3119001
• Status: Completed
• Phase: Phase 2
• First received: June 8, 2015
• Last updated: November 24, 2017
• Start date: July 2015
• Est. completion date: June 2017

Study information

• Verified date: August 2016
• Source: Orion Corporation, Orion Pharma
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

In the double-blind, cross-over part of the study, ODM-109 capsules and placebo capsules for ODM-109 will be administered for 2 weeks separated by a 19-23 days wash-out period. During each treatment period of the double-blind cross-over part, there will be a baseline visit (day 1) and 2 visits (5 ± 2 and 14 ± 2 days) after the start of study treatment. After completing the 3rd treatment period, the subjects will continue in the open-label follow-up part for 6 months. During the open-label follow-up, visits will be at 1, 3 and 6 months. An end-of-study visit will take place 14-25 days after the last study treatment administration for each subject. The study duration will be about 13-14 weeks for the double-blind cross-over part, and about 9-10 months for the entire study including the 6 months open-label follow-up.

The number of randomised study subjects is planned to be approximately 54 in cross-over comparison. The maximum number of subjects will not exceed 70.

Primary objective is to investigate the efficacy of oral ODM-109 on respiratory function in patients with amyotrophic lateral sclerosis (ALS).

Recruitment information / eligibility

• Status: Completed
• Enrollment: 66
• Est. completion date: June 2017
• Est. primary completion date: May 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Written informed consent (IC) for participation in the study will be obtained from the subject (or from the subject's next of kin, caregiver, or other legally acceptable representative in case the study subject him/herself cannot sign the IC due to severe muscle weakness).

• Age of at least 18 years.

• Male or female subjects with diagnosis of laboratory supported probable, probable or definite ALS according to El Escorial revised criteria (Brooks BR et al., 2000). Full electromyogram (EMG) report available compatible with ALS according to an experienced neurophysiologist.

• Ability to swallow the study treatment capsules.

• An upright (sitting position) SVC between 60-90% of the predicted value for age, height and sex at screening visit.

• Normal oxygen saturation during daytime (measure of = 95% when steady state has been reached with a reliable read) in sitting position measured by pulse oximetry.

• Disease duration from symptom onset (defined by first muscle weakness or dysarthria) of 12-48 months.

• Using riluzole. The dose must have been stable for at least 4 weeks prior to screening at a dose of 50 mg b.i.d.

Exclusion Criteria:

• Subject in whom other causes of neuromuscular weakness have not been excluded.

• Subject with a diagnosis of another neurodegenerative disease (e.g. Parkinson's or Alzheimer's disease).

• Assisted ventilation or gastrostomy of any type during the preceding 3 months prior to screening or predicted to be required within the randomised, double-blind cross-over part of the study.

• Recorded diagnosis or evidence of major psychiatric diagnosis, significant cognitive impairment or clinically evident dementia.

• Any major surgery within 1 month before the screening visit or patients who are scheduled for any major surgery during the planned study period.

• Potassium < 3.7 mmol/l or > 5.5 mmol/l at screening.

• Creatinine > 170 µmol/l at screening or on dialysis.

• Blood haemoglobin < 10 g/dl at screening.

• Clinically significant hepatic impairment at the discretion of the investigator.

• Women of reproductive age without a negative pregnancy test and without a commitment to using an acceptable method of barrier or hormonal contraception (e.g. condoms, diaphragms, oral contraceptives and long acting progestin agents), if sexually active during the study, and for 1 month after the last dose of the study treatment. Women who are postmenopausal (1 year since last menstrual cycle), surgically sterilised or who have undergone a hysterectomy are considered not to be reproductive and can be included.

• Known hypersensitivity to levosimendan.

• Administration of levosimendan within 30 days prior to screening visit.

• Patients with history of botulinum toxin treatment for any reason.

• Patients with known history of human immunodeficiency virus infection.

• History of significant arrhythmias or other cardiac events

• Any other clinically significant cardiovascular, pulmonary, gastrointestinal, hepatic, renal, neurological or psychiatric disorder or any other major concurrent illness that in the opinion of the investigator could interfere with the interpretation of the study results or constitute a health risk for the subject if he/she took part in the study.

• Blood donation or loss of significant amount of blood within 60 days prior to screening.

• Participation in a clinical trial with any experimental treatment within 30 days prior to the screening visit or previous participation in the present study.

• Any other condition that in the opinion of the investigator could interfere with the interpretation of the study results or constitute a health risk for the subject if he/she took part in the study.

Related Conditions & MeSH terms

• Amyotrophic Lateral Sclerosis
• Motor Neuron Disease
• Sclerosis

Intervention

Drug:
• ODM-109
ODM-109 1 mg capsule for oral administration.
• Placebo for ODM-109
Placebo capsule for oral administration.

Locations

Country	Name	City	State
Germany	Charite Universitatsmedizin Berlin	Berlin
Germany	Medical School Hannover	Hannover
Germany	University Clinical Jena	Jena
Germany	University Hospital of Ulm	Ulm
Ireland	Beaumont Hospital	Dublin
Netherlands	University Medical Centre Utrecht	Utrecht
United Kingdom	Royal Sussex County Hospital	Brighton
United Kingdom	The Walton Centre	Liverpool
United Kingdom	London Kings College Hospital	London
United Kingdom	Royal London Hospital	London
United Kingdom	University of Sheffield	Sheffield

Sponsors (1)

Lead Sponsor	Collaborator
Orion Corporation, Orion Pharma

Countries where clinical trial is conducted

Germany,  Ireland,  Netherlands,  United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Slow vital capacity SVC	Pulmonary assessment	9 months
Secondary	Hand grip strength and submaximal hand grip strength endurance	Assessment	3 months
Secondary	Changes in subject's clinical condition (relative to the baseline/day 1 of the given treatment period) will be assessed using the Clinical Global Impression of Change (CGI-C)	Scales	3 months
Secondary	Quality of life	Questionnaire	9 months
Secondary	Revised ALS Functional Rating Scale ALSFRS-R	Scale	9 months
Secondary	Oxygen saturation	Assessment	9 months
Secondary	The concentrations of ODM-109, OR-1855 and OR-1896	Pharmacokinetics Blood samples.	3 months
Secondary	Determination of subject's acetylation status	Pharmacogenomics Blood samples.	1 day (once at baseline)
Secondary	Sniff nasal pressure SNP	SNP will be assessed in sitting position. SNP will be performed for 10 times. The highest value (cmH2O) measured will be the SNP variable.	9 months
Secondary	Fatigue assessment	Visual analogue Scale VAS	3 months